With the application of anti-CTLA-4 or anti-PD-1 antibodies, the activity of glucose metabolism of T cells can be restored, and glycolysis in tumor cells can be suppressed by reducing the expression of mTOR and glycolysis-related genes (57). This evidence concerns the gene MTOR and neoplasm.